RESUMO
INTRODUCTION: This longitudinal study was based on the outcomes of Donor Lymphocyte Infusion (DLI) for falling peripheral blood (PB) CD34+ and CD3+ donor chimerism (DC). METHODS: From 2012 to 2018, data was collected from the BMT database and electronic medical records (EMR). The primary objective was to compare the indication for DLI based on falling PB CD34+ or CD3+ DC in patients post allo-SCT for AML and MDS and their overall survival (OS). RESULTS: 18/70 patients met the inclusion criteria. Indications for DLI were i) falling PB CD34+ DCâ¯≤â¯80â¯% with morphological relapse, ii) falling PB CD34+ DCâ¯≤â¯80â¯% without morphological relapse and iii) falling PB CD3+ DCâ¯≤â¯80â¯% without falling PB CD34+ DC. Log rank analysis showed falling PB CD34+ DC and morphological relapse had significantly lower OS. Linear regression demonstrated better OS post DLI if there was PB CD34+ and CD3+ chimerism response at 30 days (pâ¯=â¯0.029), GVHD (pâ¯=â¯0.032) and tapering immunosuppression at the time of falling DC (pâ¯=â¯0.042). CONCLUSION: DLI for PB CD34+ DC valuesâ¯≤â¯80â¯% and morphological relapse had the lowest OS. In this study, full DC was achieved after DLI even with a PB CD3+DC value as low as 13â¯%, provided the PB CD34+ DC remained >â¯80â¯%. Further research is vital in CD34+ DC as a biomarker for disease relapse and loss of engraftment.
Assuntos
Antígenos CD34 , Leucemia Mieloide Aguda , Transfusão de Linfócitos , Síndromes Mielodisplásicas , Transplante Homólogo , Humanos , Síndromes Mielodisplásicas/terapia , Síndromes Mielodisplásicas/patologia , Síndromes Mielodisplásicas/mortalidade , Masculino , Feminino , Leucemia Mieloide Aguda/terapia , Leucemia Mieloide Aguda/mortalidade , Leucemia Mieloide Aguda/patologia , Leucemia Mieloide Aguda/imunologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Adulto , Estudos Longitudinais , Antígenos CD34/análise , Idoso , Transplante de Células-Tronco Hematopoéticas/métodos , Complexo CD3/análise , Quimeras de Transplante , Adulto Jovem , Doadores de Tecidos , Doença Enxerto-Hospedeiro/etiologia , Doença Enxerto-Hospedeiro/diagnósticoRESUMO
INTRODUCTION: Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and ciclosporin is standard of care for patients with severe aplastic anaemia (sAA) not eligible or suitable for allogeneic stem cell transplant. While patients respond to IST, few achieve complete responses and a significant proportion are refractory or relapse. The addition of eltrombopag, a thrombopoietin-receptor agonist (TPO-A), to IST has been shown to improve haematological responses in sAA. Avatrombopag is a second-generation TPO-A with potential advantages over eltrombopag. However, to date avatrombopag has not been studied in sAA. METHODS AND ANALYSIS: Investigator-initiated, single-arm registry-based Bayesian Optimal Phase II trial of avatrombopag conducted in two cohorts, patients with untreated sAA (FIRST cohort) and in patients with sAA that has relapsed or is refractory to IST (NEXT cohort). In the FIRST cohort, participants receive IST (equine ATG and ciclosporin) plus avatrombopag from day 1 until day 180 at 60 mg oral daily, with dose adjusted according to platelet count. Participants in the NEXT cohort receive avatrombopag at 60 mg oral daily from day 1 until day 180, with or without additional IST at the discretion of the treating clinician.For each cohort, two primary endpoints (haematological response and acquired clonal evolution) are jointly monitored and the trial reviewed at each interim analysis where a 'go/no-go' decision is made by evaluating the posterior probability of the events of interests. ETHICS AND DISSEMINATION: The trial has received ethics approval (Monash Health RES-18-0000707A). The trial conduct will comply with ICH-GCP and all applicable regulatory requirements. The results of the trial will be submitted to a peer-review journal for publication. TRIAL REGISTRATION NUMBER: ACTRN12619001042134, ACTRN12619001043123.